Search results for "Highlights"


 
Results 121 - 130 of about 323 for "Highlights".

Approved drugs for diabetic neuropathy better than placebo, review finds

In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
April 2017

Screening tool identifies high-risk drivers with type 1 diabetes and website helps to avoid future accidents

Significant independent predictors of risk for driving mishaps included annual driving distance and presence of peripheral neuropathy. Researchers developed an 11-item questionnaire to further refine risk prediction.
May 2017

Higher prevalence of complications in young adults diagnosed with type 2 vs. type 1 diabetes

Compared to those with type 1 diabetes, participants with type 2 had a significantly higher age-adjusted prevalence of diabetic kidney disease, retinopathy, peripheral, arterial stiffness, and hypertension by age 21.
March 2017

Dapagliflozin associated with lower risk for all-cause mortality in type 2 diabetes regardless of CVD risk, study finds

The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
March 2017

Supplemental triglyceride-lowering therapy may lower CVD risk in statin-treated patients with diabetic dyslipidemia, study finds

The rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes was 27% lower in participants with dyslipidemia randomized to fenofibrate than among those randomized to placebo.
January 2017

ACP releases updated guideline on oral pharmacologic treatment of type 2 diabetes

ACP recommended that clinicians prescribe metformin for type 2 diabetes when pharmacologic therapy is needed to improve glycemic control in a strong recommendation based on moderate-quality evidence.
January 2017

Clinicians should integrate psychosocial components into diabetes care, ADA recommends

The position statement recommends that physicians consider assessing cognitive capacities and symptoms of diabetes distress, depression, anxiety, and disordered eating at the initial visit and at periodic intervals.
December 2016

Highlights

Results from this small study suggest that reducing adipose tissue volume, by whatever means, will improve blood glucose control in patients with type 2 diabetes, an accompanying editorial noted.
September 2020

Spotlight on cognitive effects of diabetes

Our findings also highlight the need for early intervention aimed to reduce risk factors for overweight or obesity in type 2 diabetic individuals to preserve their brain structure and cognitive function,”
May 2017

Continuous glucose monitoring associated with lower HbA1c in type 1 diabetes treated with insulin injection

An editorial accompanying the two trials of continuous glucose monitoring stressed that the physicians involved had extensive experience with the technology and noted that the necessary changes in lifestyle and insulin dosing can be variable and
February 2017

Result Page: Prev   8   9   10   11   12   13   14   15   16   17   Next